JP2024501471A5 - - Google Patents
Info
- Publication number
- JP2024501471A5 JP2024501471A5 JP2023535799A JP2023535799A JP2024501471A5 JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5 JP 2023535799 A JP2023535799 A JP 2023535799A JP 2023535799 A JP2023535799 A JP 2023535799A JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- approximately
- pharmaceutical composition
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125371P | 2020-12-14 | 2020-12-14 | |
| US63/125,371 | 2020-12-14 | ||
| PCT/US2021/063130 WO2022132652A1 (en) | 2020-12-14 | 2021-12-13 | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501471A JP2024501471A (ja) | 2024-01-12 |
| JP2024501471A5 true JP2024501471A5 (enExample) | 2024-12-23 |
Family
ID=79288002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535799A Pending JP2024501471A (ja) | 2020-12-14 | 2021-12-13 | エストロゲン受容体分解剤としてのテトラヒドロナフタレン誘導体を用いる乳がんを治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220193072A1 (enExample) |
| EP (1) | EP4259137A1 (enExample) |
| JP (1) | JP2024501471A (enExample) |
| KR (1) | KR20230121801A (enExample) |
| CN (1) | CN116744925A (enExample) |
| AU (1) | AU2021401580A1 (enExample) |
| CA (1) | CA3202592A1 (enExample) |
| IL (1) | IL303143A (enExample) |
| MX (1) | MX2023007058A (enExample) |
| TW (1) | TW202237117A (enExample) |
| WO (1) | WO2022132652A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| CN115746058A (zh) * | 2021-09-03 | 2023-03-07 | 南京知和医药科技有限公司 | 一种多环化合物在制备抗肿瘤药物方面的用途 |
| US20260028354A1 (en) * | 2022-07-12 | 2026-01-29 | Regent Of The University Of Michigan | Tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN120112291A (zh) * | 2022-08-31 | 2025-06-06 | 阿尔维纳斯运营股份有限公司 | 雌激素受体降解剂的给药方案 |
| WO2024196053A1 (ko) * | 2023-03-17 | 2024-09-26 | 재단법인 대구경북첨단의료산업진흥재단 | 에스트로겐-연관 수용체 감마 억제제 및 항암제의 병용요법용 조성물 |
| TW202440096A (zh) * | 2023-03-24 | 2024-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| EP4719399A1 (en) * | 2023-06-02 | 2026-04-08 | Arvinas Operations, Inc. | Combinations of estrogen receptor degraders and akt inhibitors |
| CN121368483A (zh) * | 2023-06-02 | 2026-01-20 | 辉瑞公司 | 雌激素受体降解剂与cdk4抑制剂的组合 |
| WO2025122502A1 (en) * | 2023-12-04 | 2025-06-12 | Foundation Medicine, Inc. | Methods for treating hr-positive her2-negative breast cancer |
| WO2026007884A1 (zh) * | 2024-07-04 | 2026-01-08 | 海创药业股份有限公司 | 一种雌激素受体降解剂和akt抑制剂联合用药物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2015136016A2 (en) * | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| KR20250152679A (ko) * | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| IL302595A (en) * | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| CA3121930A1 (en) * | 2018-12-06 | 2020-06-11 | Radius Pharmaceuticals, Inc. | Methods for treating cancer resistant to cdk4/6 inhibitors |
| KR20220054347A (ko) * | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
-
2021
- 2021-12-13 AU AU2021401580A patent/AU2021401580A1/en active Pending
- 2021-12-13 CA CA3202592A patent/CA3202592A1/en active Pending
- 2021-12-13 WO PCT/US2021/063130 patent/WO2022132652A1/en not_active Ceased
- 2021-12-13 JP JP2023535799A patent/JP2024501471A/ja active Pending
- 2021-12-13 EP EP21840327.7A patent/EP4259137A1/en active Pending
- 2021-12-13 US US17/548,842 patent/US20220193072A1/en active Pending
- 2021-12-13 CN CN202180092119.4A patent/CN116744925A/zh active Pending
- 2021-12-13 IL IL303143A patent/IL303143A/en unknown
- 2021-12-13 TW TW110146570A patent/TW202237117A/zh unknown
- 2021-12-13 MX MX2023007058A patent/MX2023007058A/es unknown
- 2021-12-13 KR KR1020237023551A patent/KR20230121801A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501471A5 (enExample) | ||
| US12280050B2 (en) | Therapeutic compositions, combinations, and methods of use | |
| US20120157472A1 (en) | Method for treating colorectal cancer | |
| CN101677977A (zh) | 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合 | |
| JP2024533423A (ja) | 薬学的組成物およびその使用 | |
| EP2662082A1 (en) | Administration of mTOR inhibitors | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| WO2023081830A2 (en) | Compositions and treatments with nirogacestat | |
| TWI719765B (zh) | 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療 | |
| JP2025163103A (ja) | 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| TW201309298A (zh) | 治療惡性神經膠質瘤之醫藥組合物 | |
| US20250186446A1 (en) | Organic compounds | |
| CN118678958A (zh) | 药物组合物及其用途 | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| CN119894514A (zh) | 药物组合物及其用途 | |
| HK40116696A (zh) | 药物组合物及其用途 | |
| HK40110967A (zh) | 药物组合物及其用途 |